Myriad is a pioneer in the field of companion diagnostics. In essence, companion diagnostics are tests being developed to identify patients most likely to benefit from specific treatments based on their own genetic makeup and biology. Companion diagnostics hold tremendous promise in the treatment of diseases such as rheumatoid arthritis and other autoimmune disorders, cancer and diabetes.

Below are some of the promising companion diagnostics that Myriad is developing in collaboration with outside partners:

  • BRACAnalysis CDx™ is a companion diagnostic test that uses a blood sample to identify germline mutations in the BRCA1 and BRCA2 genes;
  • Tumor BRACAnalysis CDxTM is a companion diagnostic test that analyzes tumor tissue to identify somatic mutations in BRCA1 and BRCA2 genes; and
  • myChoice HRD™ is a companion diagnostic that detects when a tumor has lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to medicines that target a deficiency in the DNA repair pathway.

 

BRACAnalysis CDx™ Partnerships

Company Drug Clinical Trial Phase/Indication Timeline
AstraZeneca olaparib Phase 3 – maintenance therapy for platinum sensitive relapsed ovarian cancer

Phase 3 – first line maintenance therapy for ovarian cancer

Phase 3 – metastatic breast cancer

Phase 3 – salvage therapy ovarian cancer

Phase 3 – adjuvant breast cancer

Phase 3 – metastatic pancreatic cancer

Received U.S. FDA and EMA approval for maintenance therapy platinum sensitive ovarian cancer in CY2014. Expect to file with the FDA for breast cancer in CY16.
Medivation talazoparib Phase 3 – metastatic breast cancer NA
TESARO niraparib Phase 3 – maintenance therapy for platinum sensitive ovarian cancer

Phase 3 – metastatic breast cancer

Q2 CY16
Abbvie velaparib Phase 3 clinical trials in neo-adjuvant and metastatic breast cancer NA

myChoice HRD™ Partnerships

Company Drug Clinical Trial Phase/Indication Timeline
TESARO niraparib Phase 3 – maintenance therapy for platinum Q2 CY16
Medivation talazoparib Research collaboration NA
TESARO niraparib Research collaboration NA
AbbVie veliparib Research collaboration NA

*The use of the tests described in this section for companion diagnostic purposes may be considered to be investigational and subject to FDA medical device and other applicable regulations.

 

Key partnerships include:

Myriad engages with leading industry partners